









Markets
/
Stocks
/
nasdaq-abbv
/

AbbVie Inc

ABBV

228.200USD

+3.060+1.36%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

403.11BMarket Cap

108.27P/E TTM



AbbVie Inc

228.200

+3.060+1.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AbbVie Inc

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AbbVie Inc's Score

Industry at a Glance

Industry Ranking

42 / 159

Overall Ranking

115 / 4621

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 31 analysts

Buy

Current Rating

237.899

Target Price

+5.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

AbbVie Inc Highlights

StrengthsRisks

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 263.76%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 263.76%.

Overvalued

The company’s latest PE is 108.39, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.31B shares, decreasing 0.80% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 1.37M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 8.82, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.42B, representing a year-over-year increase of 6.65%, while its net profit experienced a year-over-year increase of 31.76%.

Score

Industry at a Glance

Previous score

8.82

Change



Financials

5.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.65

Key Metrics

Free cash flow

No Data

AbbVie Inc's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 5.05, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 108.39, which is 7.09% below the recent high of 116.08 and 79.95% above the recent low of 21.74.

Score

Industry at a Glance

Previous score

5.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 7.81, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for AbbVie Inc is 242.50, with a high of 284.00 and a low of 187.13.

Score

Industry at a Glance

Previous score

7.81

Change

Support & Resistance

No Data

Analyst Rating

Based on 31 analysts

Buy

Current Rating

237.899

Target Price

+5.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

AbbVie Inc

ABBV

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.91, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 236.68 and the support level at 221.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.35

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-2.050

Neutral

RSI(14)

52.945

Neutral

STOCH(KDJ)(9,3,3)

36.251

Neutral

ATR(14)

3.352

Low Volatility

CCI(14)

-22.328

Neutral

Williams %R

57.399

Sell

TRIX(12,20)

0.075

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

227.380

Buy

MA10

228.685

Sell

MA20

229.437

Sell

MA50

222.200

Buy

MA100

207.236

Buy

MA200

199.316

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.81. The latest institutional shareholding proportion is 74.32%, representing a quarter-over-quarter decrease of 0.81%. The largest institutional shareholder is The Vanguard, holding a total of 176.50M shares, representing 9.99% of shares outstanding, with 2.47% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

176.50M

+1.94%

BlackRock Institutional Trust Company, N.A.

92.10M

+1.18%

State Street Investment Management (US)

80.02M

+0.08%

Geode Capital Management, L.L.C.

39.18M

+2.42%

JP Morgan Asset Management

37.47M

+5.24%

Charles Schwab Investment Management, Inc.

26.78M

+6.01%

Capital Research Global Investors

25.27M

-24.60%

Morgan Stanley Smith Barney LLC

23.51M

+1.10%

Norges Bank Investment Management (NBIM)

23.10M

-7.94%

Fidelity Management & Research Company LLC

19.65M

-8.30%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 9.60, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.